Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen
Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate...
Stay updated with breaking news from Solid Tumour. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate...
Candidate is first molecule targeting an RNA methyltransferase enzyme to enter development - News - PharmaTimes
New Delhi [India], October 21 (ANI/SRV): Surat Hematology Centre, one of the leading Hematology centres in Surat, recently celebrated a landmark achievement of the 50th successful Bone Marrow Transplant. The Centre specialises in Bone Marrow Transplants and the treatment of blood disorders in the South Gujarat region and has some of the best Hematologists in Surat as their founders. The centre has achieved this remarkable feat in a very short period of time. The centre was established by two visionaries sharing the same passion, Dr Hasmukh R Balar and Dr Dharmesh Vaghasiya, both being Hemato-O...
QBiotics Group Limited (QBiotics), a life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals, is pleased to announce that it has dosed the first patient in the Phase Ib/IIa clinical trial of the company's lead oncology molecule, tigilanol tiglate in combination with MSD's immune checkpoint inhibitor KEYTRUDA® (pembrolizumab) for patients with unresectable melanoma, the deadliest form of skin cancer.
AVA6000 is pro-drug form of the chemotherapy doxorubicin, modified using Avacta's pre|CISION chemistry - News - PharmaTimes